Mitchell P Kopin stated that they own 6.4% of Apricus Biosciences Inc. (NASDAQ:APRI) in a Schedule 13G disclosure that was filed with the Securities and Exchange Commission (SEC) on Monday, October 3rd. The investor owns 4,954,938 shares of the stock worth about $1,708,958. The reporting parties listed on the disclosure included Mitchell P Kopin, Daniel B Asher and Intracoastal Capital LLC. The filing is available through EDGAR at this hyperlink.

Separately, Vanguard Group Inc. raised its stake in shares of Apricus Biosciences by 0.7% in the second quarter. Vanguard Group Inc. now owns 1,511,841 shares of the company’s stock worth $604,000 after buying an additional 9,786 shares in the last quarter. 23.83% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Apricus Biosciences (NASDAQ:APRI)

Apricus Biosciences Inc. (NASDAQ:APRI) traded up 1.9509% during mid-day trading on Monday, hitting $0.3449. The company had a trading volume of 319,341 shares. Apricus Biosciences Inc. has a 52-week low of $0.28 and a 52-week high of $1.68. The company has a 50-day moving average price of $0.35 and a 200 day moving average price of $0.46. The company’s market capitalization is $22.88 million.

Apricus Biosciences (NASDAQ:APRI) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($0.05) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. During the same period last year, the company earned ($0.10) EPS. On average, analysts forecast that Apricus Biosciences Inc. will post ($0.17) EPS for the current fiscal year.

Separately, Zacks Investment Research lowered shares of Apricus Biosciences from a “buy” rating to a “hold” rating in a research note on Tuesday, July 26th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $1.90.

About Apricus Biosciences

Apricus Biosciences, Inc is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT.

5 Day Chart for NASDAQ:APRI

Want to see what other hedge funds are holding APRI? Visit to get the latest 13F filings and insider trades for Apricus Biosciences Inc. (NASDAQ:APRI).

Receive News & Ratings for Apricus Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apricus Biosciences Inc. and related companies with's FREE daily email newsletter.